All In Biotech

Drug Trial Radar · NCT04797247

Study of Efficacy and Safety of LIB003 in Patient With CVD on Statins Requiring Additional LDL-C Reduction

Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction

Last checked: Nov 20, 2026Latest source record: Dec 11, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknownPivotal-lookingPhase 3. Randomized with 900 participants. This is a heuristic, not a regulatory label.

Status

Status unknown

Enrollment

900

Planned (sponsor's estimate)

Start

Apr 22, 2021

Primary completion

Nov 15, 2023

Study completion Feb 28, 2024

Sponsor

Lead sponsor
LIB Therapeutics LLCIndustry
Sponsor type
Industry
Collaborators
Medpace, Inc.
First posted
Mar 15, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is to assess LDL-C reductions at Week 52 with monthly (Q4W \[≤31 days\]) dosing of LIB003 (lerodalcibep) 300 mg administered subcutaneously (SC) compared to placebo in patients with very-high risk for CVD on a stable diet and oral LDL-C lowering drug therapy.

Conditions

  • Cardiovascular Diseases
  • Hyper-LDL-cholesterolemia

Interventions

  • lerodalcibepDrug

    PCSK9 inhibitor

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. LDL-C change compared to placeboTime frame: 52 weeks
  2. mean LDL-C change at week 50 and 52Time frame: 52 weeks

Locations

3 sites in 1 country. Site status is shown where the registry gives one.

  • Sterling Research Group

    Cincinnati, Ohio

  • The Lindner Research Center

    Cincinnati, Ohio

  • Metabolic & Atherosclerosis Research Center (MARC)

    Cincinnati, Ohio

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.